Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833476 · ClinicalTrials.gov registry record
TTVR STRONG Under Coverage With Evidence Development (CED) Study
A clinical trial of Tricuspid Regurgitation, sponsored by Edwards Lifesciences.
- Recruiting
- Registry status
- 2,044
- Enrollment target
- 1
- Study location
NCT06833476: Recruiting study of Tricuspid Regurgitation, sponsored by Edwards Lifesciences.
NCT06833476 is a study of Tricuspid Regurgitation that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 2,044 participants, above the 415-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (393% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06833476, a study of Tricuspid Regurgitation, is actively recruiting participants, sponsored by Edwards Lifesciences.
- RECRUITING
- Registry status
- 2,044 participants
- Enrollment target
- 1
- Study location
Study Summary
This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.
Primary Outcome
Time to death or heart failure hospitalization after time zero
Conditions Studied
Interventions
- OTHER EVOQUE
Study Locations (1)
California
- Edwards Lifesciences - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,044 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2032-12-31 |
What NCT06833476 shows while recruiting
NCT06833476 is an observational study that tracks outcomes without assigning an intervention. Its 2,044 participants enrollment target places it among the larger protocols in the corpus, above the 415-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (393% higher).
The record links to 1 condition, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which EVOQUE is the first listed.
NCT06833476 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06833476 about?
NCT06833476 is a clinical study titled "TTVR STRONG Under Coverage With Evidence Development (CED) Study". This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.
What is the current status of trial NCT06833476?
This trial is currently recruiting. The enrollment target is 2,044 participants. The study started on 2025-03-19. Estimated completion is 2032-12-31.
What conditions does trial NCT06833476 study?
This clinical trial studies the following conditions: Tricuspid Regurgitation.
What interventions are being tested in trial NCT06833476?
The interventions under investigation include: EVOQUE (OTHER).
Who is sponsoring clinical trial NCT06833476?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06833476 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tricuspid Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06833476's enrollment target sits among peer trials
2,044 2nd of 17 the highest of 17 other Tricuspid Regurgitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tricuspid Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
RECRUITING
-
TTVR Early Feasibility Study
RECRUITING · NA
-
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
RECRUITING · NA
-
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
RECRUITING · NA
-
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
RECRUITING · NA
-
Trisol System EFS Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05138718 · 2,041 participants
FDG an Myocardial Infarction: The PIAF Trial
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
- NCT06825897 · 2,039 participants · NA
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI